https://www.whitehouse.gov/wp-content/uploads/2021/05/budget_fy22.pdf
Urica Therapeutics Expands Exclusive License Agreement With Fuji Yakuhin Co. Ltd. To Develop Dotinurad In Additional Territories Including Turkey, Middle East And North Africa
Urica Therapeutics, Inc. ("Urica" or the "Company") (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary company focused on the
